Ascentage Pharma presents improved ORR data for Lisaftoclax in R/R MM & AL Amyloidosis at EHA 2024.
Ascentage Pharma presents updated data on Lisaftoclax in R/R MM & AL Amyloidosis patients at EHA 2024, highlighting a marked improvement in ORR. The Bcl-2 inhibitor, Lisaftoclax (APG-2575), combined with novel therapeutic regimens, shows promising results in patients with relapsed/refractory multiple myeloma or immunoglobulin light-chain amyloidosis. This data was shared at the 2024 European Hematology Association Hybrid Congress in Madrid, Spain.
June 18, 2024
3 Articles